Trial Testing Ketamine as Dyskinesia Treatment Soon Enrolling Patients

Trial Testing Ketamine as Dyskinesia Treatment Soon Enrolling Patients

308551

Trial Testing Ketamine as Dyskinesia Treatment Soon Enrolling Patients

A new Phase 2 clinical trial will test the psychedelic painkiller ketamine as a treatment for levodopa-induced dyskinesia in people with Parkinson’s disease. The trial, called KET-LID (NCT04912115), is expected to start enrolling participants this month. The first results are expected by the end of the year. Launched by PharmaTher, the study will evaluate ketamine’s safety, efficacy, and pharmacokinetics — the medicine’s movement into, through, and out of the body — in treating dyskinesia, the uncontrolled, involuntary movements that…

You must be logged in to read/download the full post.